HK1199412A1 - (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders - Google Patents

(bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders Download PDF

Info

Publication number
HK1199412A1
HK1199412A1 HK14113090.6A HK14113090A HK1199412A1 HK 1199412 A1 HK1199412 A1 HK 1199412A1 HK 14113090 A HK14113090 A HK 14113090A HK 1199412 A1 HK1199412 A1 HK 1199412A1
Authority
HK
Hong Kong
Prior art keywords
chlorophyll
disorders
treatment
bacterio
photosensitizers
Prior art date
Application number
HK14113090.6A
Other languages
English (en)
Chinese (zh)
Inventor
Avigdor Scherz
Yoram Salomon
Arie MARCOVICH
Alexander Brandis
Daniel Wagner
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of HK1199412A1 publication Critical patent/HK1199412A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0613Apparatus adapted for a specific treatment
    • A61N5/062Photodynamic therapy, i.e. excitation of an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0658Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659Radiation therapy using light characterised by the wavelength of light used infrared

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14113090.6A 2011-08-23 2012-08-23 (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders HK1199412A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526414P 2011-08-23 2011-08-23
US61/526,414 2011-08-23
PCT/IL2012/050325 WO2013027222A1 (en) 2011-08-23 2012-08-23 (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders

Publications (1)

Publication Number Publication Date
HK1199412A1 true HK1199412A1 (en) 2015-07-03

Family

ID=46889394

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14113090.6A HK1199412A1 (en) 2011-08-23 2012-08-23 (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders

Country Status (20)

Country Link
US (4) US9452172B2 (enExample)
EP (1) EP2747763B1 (enExample)
JP (1) JP6215203B2 (enExample)
KR (1) KR101962991B1 (enExample)
CN (1) CN103930108B (enExample)
AU (1) AU2012298156B2 (enExample)
BR (1) BR112014004306A2 (enExample)
CA (1) CA2846011C (enExample)
CL (1) CL2014000432A1 (enExample)
DK (1) DK2747763T3 (enExample)
ES (1) ES2856698T3 (enExample)
HK (1) HK1199412A1 (enExample)
HU (1) HUE053321T2 (enExample)
IN (1) IN2014CN02153A (enExample)
MX (1) MX360683B (enExample)
PE (1) PE20141183A1 (enExample)
PT (1) PT2747763T (enExample)
RU (1) RU2632439C2 (enExample)
WO (1) WO2013027222A1 (enExample)
ZA (1) ZA201402056B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
JP6049712B2 (ja) 2011-07-08 2016-12-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子
EP2830637B1 (en) 2012-03-29 2024-08-21 Epion Therapeutics, Inc. Compositions and methods for treating or preventing diseases associated with oxidative stress
EP2830627B1 (en) 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
CN116832158A (zh) 2015-07-21 2023-10-03 艾维德洛公司 用光敏剂治疗眼睛的系统和方法
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
CN105601638B (zh) * 2016-01-28 2018-10-26 东北林业大学 一种叶绿酸衍生物及其制备方法、作为光敏抑菌剂及光敏杀虫剂的应用
EP3442481B1 (en) 2016-04-13 2023-06-28 Avedro, Inc. Systems for delivering drugs to an eye
US20170319329A1 (en) * 2016-05-05 2017-11-09 David Muller Corneal Implant Systems and Methods
CA3046668A1 (en) * 2017-01-03 2018-07-12 Vitrean, Inc. Methods and devices for treating a retinal detachment
CN111194232B (zh) * 2017-08-02 2023-01-31 芝加哥大学 纳米级金属有机层和金属有机纳米片
CN109091685A (zh) * 2018-08-10 2018-12-28 北京市眼科研究所 一种对角膜炎提取细菌病原体的灭活方法
WO2020086697A1 (en) * 2018-10-24 2020-04-30 California Institute Of Technology Treatment of myopia and other ocular conditions using singlet oxygen
US11702546B2 (en) 2018-10-24 2023-07-18 California Institute Of Technology Near-infrared heptamethine dyes for generation of singlet oxygen
EP3890741A1 (en) * 2018-12-04 2021-10-13 Avedro Inc. Compounds and compositions for eye treatments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102645A (en) 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
RU2201219C2 (ru) * 2001-04-24 2003-03-27 Макаров Константин Алексеевич Фармакологическая композиция пролонгированного действия
WO2003028628A2 (en) 2001-10-03 2003-04-10 Miravant Pharmaceuticals, Inc. Photosensitizing carbamate derivatives
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
CN1980661B (zh) * 2004-06-07 2011-09-28 耶达研究及发展有限公司 阳离子细菌叶绿素衍生物及其用途
JP2010502574A (ja) * 2006-08-23 2010-01-28 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Rgdペプチドとポルフィリン又は(バクテリオ)クロロフィル光合成剤とのコンジュゲート及びその使用
KR101551590B1 (ko) 2006-10-24 2015-09-08 캘리포니아 인스티튜트 오브 테크놀로지 신체 조직의 물리적 및/또는 화학적 성질에 영향을 주는 광화학적 요법
RU2404768C1 (ru) * 2009-10-28 2010-11-27 Федеральное агентство по науке и инновациям Глазные капли
WO2011099602A1 (ja) * 2010-02-12 2011-08-18 学校法人日本大学 ポルフィリン誘導体および放射線力学療法におけるその使用

Also Published As

Publication number Publication date
KR20140088514A (ko) 2014-07-10
AU2012298156A1 (en) 2014-04-10
KR101962991B1 (ko) 2019-03-27
HUE053321T2 (hu) 2021-06-28
BR112014004306A2 (pt) 2017-03-28
ZA201402056B (en) 2015-11-25
US20210330792A1 (en) 2021-10-28
ES2856698T3 (es) 2021-09-28
RU2632439C2 (ru) 2017-10-04
CL2014000432A1 (es) 2014-11-28
RU2014110784A (ru) 2015-09-27
PE20141183A1 (es) 2014-10-05
AU2012298156B2 (en) 2017-08-17
CA2846011A1 (en) 2013-02-28
EP2747763B1 (en) 2020-12-30
US20140378888A1 (en) 2014-12-25
CN103930108A (zh) 2014-07-16
US9452172B2 (en) 2016-09-27
JP2014524465A (ja) 2014-09-22
CA2846011C (en) 2019-10-15
EP2747763A1 (en) 2014-07-02
IN2014CN02153A (enExample) 2015-05-29
PT2747763T (pt) 2021-02-22
US20190231874A1 (en) 2019-08-01
WO2013027222A1 (en) 2013-02-28
US20160354468A1 (en) 2016-12-08
DK2747763T3 (da) 2021-03-29
MX2014002107A (es) 2015-04-16
CN103930108B (zh) 2017-05-24
JP6215203B2 (ja) 2017-10-18
MX360683B (es) 2018-11-13
US11058772B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
HK1199412A1 (en) (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders
HK1201438A1 (en) Treatment of ocular disease
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
BR112017024531A2 (pt) lentes intraoculares ajustáveis por luz usando nanopartículas de conversão ascendente e luz do infravermelho próximo (nir)
EA201301277A1 (ru) Композиции и способы лечения заболеваний сетчатки
WO2012103186A3 (en) Androgen composition for treating an opthalmic condition
NZ705624A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
WO2015023884A3 (en) Timed release of substances to treat ocular disorders
MY176525A (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
NZ704178A (en) Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
WO2013189606A3 (en) Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
ES2722723T3 (es) Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular
EA201490845A1 (ru) Улучшенная сшивающая композиция, доставляемая способом ионтофореза, пригодная для лечения кератоконуса
WO2013046059A3 (en) Methods and compositions for tamarind-based ocular disease treatment in combination with trehalose
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.
WO2010046865A3 (en) Ophthalmic administration of a composition including brimonidine as a mist
HK1219654A1 (zh) 用於治疗眼科疾病和病症的方法
MX2010008308A (es) Tratamiento para trastornos relacionados con los ojos.
WO2014003850A3 (en) Methods for treatment of ocular diseases
Wong Microincisional cataract surgery
UA38111U (ru) Способ предоперационной подготовки пациентов с миопией высокой степени к факоэмульсификации хрусталика с вживлением интраокулярной линзы
IL231052A0 (en) (Bacterio) chlorophyll photosensitizers for the treatment of eye diseases and disorders
WO2013074727A3 (en) Accommodative intraocular lenses using pupil miosis